---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-109166"
form_type: "8-K"
ticker: "DRIO"
cik: "0001533998"
company_name: "DarioHealth Corp."
filed_at: "2025-11-10T23:59:59+00:00"
generated_at: "2026-05-16T22:21:57.452919+00:00"
event_type: "debt"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# DarioHealth amends credit facility; resets covenants, waives Q2/Q3 tests, adds $10M liquidity covenant

## Summary
- Credit agreement amended with Callodine Commercial Finance on Nov 5, 2025.
- Financial covenant testing waived for Q2 and Q3 2025; minimum unencumbered liquid assets set at $10M.
- Additional $2.5M funding from lenders now uncommitted and discretionary; exit fee increased by $150k.
- Warrant exercise price reduced from $16.556 to $15.3495; conversion price on up to $2.5M loan reduced to $15.3495.
- Amendment fee of $150k paid; 13-week cash-flow reporting required when liquidity below $11M.

## SEC filing metadata
- accession: 0001104659-25-109166
- form_type: 8-K
- ticker: DRIO
- cik: 0001533998
- company_name: DarioHealth Corp.
- filed_at: 2025-11-10T23:59:59+00:00
- event_type: debt
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.03, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1533998/000110465925109166/0001104659-25-109166-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1533998/000110465925109166/tm2530754d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-109166
- JSON: https://secwatch.observer/filing/0001104659-25-109166.json
- Plain text: https://secwatch.observer/filing/0001104659-25-109166.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.